New data demonstrates 80% sustained weight loss
at three years with the Allurion Program and initial positive
outcomes of a novel, generative AI-powered conversational agent for
obesity treatment
Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to
ending obesity, today announced three oral scientific presentations
at the 12th Congress of the International Federation for the
Surgery of Obesity and Metabolic Disorders – European Chapter
(IFSO-EC) held in Vienna, Austria on 2-4 May 2024.
Presentations include data from a survey of 133 patients across
seven international obesity centers that shows patients on the
Allurion Program lost just over 15% of total body weight at 4
months, and maintained over 80% of their total body weight loss
three years after completing the Program. In addition, 72% of
patients reported that three years after the Program, their eating
habits had remained healthier.
Data from previous studies demonstrated that patients using the
Allurion Program maintained an average of 96% of their weight loss
one year after the Allurion Program1 , and that by using an
intensive follow up, Program patients can continue to lose weight
after balloon residency2. This survey provides additional insight
into even longer-term outcomes.
"Long-term weight maintenance after significant weight loss is
notoriously difficult to achieve,” said Dr. Shantanu Gaur, Founder
and CEO of Allurion. “The Allurion Program is intended to deliver a
significant amount of weight loss in a short period of time and
simultaneously help individuals make durable changes to their
lifestyle and behavior. These findings underscore how effective
Allurion’s comprehensive program can be in driving long-term weight
maintenance.”
Presentations will also include data on the initial experiences
with Coach Iris, Allurion’s novel, AI-powered weight loss
coach.
A study of 33 patients on the Allurion Program was conducted to
explore perceptions concerning interactions with traditional
chatbots and to inform the development of Coach Iris. Interviews
revealed chatbots were typically deemed frustrating, impersonal,
and rigid, with skepticism about their ability to provide
meaningful support. However, after real-world utilization of the
Coach Iris prototype, surveys demonstrated high satisfaction with
its support quality (94%), personalization (84%), information
accuracy (100%), and safety and trustworthiness (89%).
“Despite initial skepticism towards traditional chatbots,
patients testing Allurion’s innovative, generative AI-powered coach
felt that it was personalized, trustworthy and had an empathetic
and non-judgmental tone,” said Regina Barzilay, Ph.D., MIT
Distinguished Professor for AI and Health, and member of Allurion’s
Scientific Advisory Board. “This insight indicates that past
chatbot experiences may not dictate future acceptance of AI-powered
conversational agents, emphasizing the importance of fine-tuning
models to meet patient needs.”
Details of the oral presentations are as follows:
Title: Achieving Sustained Weight Loss at 3-Years with a
Swallowable Gastric Balloon Program Presenter: Roberta
Ienca, M.D., Weight Management Center, Nuova Villa Claudia Clinic
Presentation Date: Thursday, May 2nd, 16:30-18:00
Title: Think FAST: A novel framework to evaluate and
monitor the Fidelity, Accuracy, Safety, and Tone of an AI
Conversational Agent supporting patients receiving obesity
treatment Presenter: Martha Neary, M.Sc., Senior Manager
Behavioral Medicine, Allurion Presentation Date: Friday, May
3rd, 09:00-10:30
Title: Assessing Perceptions and Experience of Using a
Novel AI Conversational Agent Fine-Tuned for Patients on a
Swallowable Gastric Balloon Program Presenter: Zoe
Griffiths, Bsc,. RD, Senior Director Behavioral Medicine, Allurion
Presentation Date: Friday, May 3rd, 09:00-10:30
For more information about IFSO-EC, please visit:
https://www.ifso-ec2024.com/
Sources: 1. Ienca R et al., The Evolution of the Allurion
Program for Long-Term Weight Loss: From Virtual Monitoring to a
Virtual Care Suite. ZoomForward2022: European Congress on Obesity.
Obes Facts. 2022;15 Suppl 1:1-240. doi:10.1159/000524469. ; 2.
Raftopoulos Y et al. The Swallowable Gastric Balloon Significantly
Enhances an Intensive Lifestyle Intervention Program for Weight
Loss: Final Short and Long Term Results up to 1 Year after Balloon
Placement. Presented at the 37th Annual Meeting of the American
Society for Metabolic & Bariatric Surgery; June 10-12, 2021;
virtual.
About Allurion
Allurion is dedicated to ending obesity. The Allurion Program is
a weight loss platform that features the Allurion Gastric Balloon,
the world’s first and only swallowable, procedure-less intragastric
balloon for weight loss, and offers access to the Allurion Virtual
Care Suite, including the Allurion Mobile App for consumers,
Allurion Insights for health care providers featuring the Coach
Iris AI Platform, and the Allurion Connected Scale. The Allurion
Virtual Care Suite is also available to providers separately from
the Allurion Program to help customize, monitor and manage weight
loss therapy for patients regardless of their treatment plan:
gastric balloon, surgical, medical or nutritional. The Allurion
Gastric Balloon is an investigational device in the United
States.
For more information about Allurion and the Allurion Virtual
Care Suite, please visit www.allurion.com
Allurion is a trademark of Allurion Technologies, Inc. in the
United States and countries around the world.
Forward-Looking Statements
This press release may contain certain forward-looking
statements within the meaning of the U.S. federal and state
securities laws. These forward-looking statements generally are
identified by the words “believe,” “project,” “expect,”
“anticipate,” “estimate,” “intend,” “strategy,” “future,”
“opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,”
“will continue,” “will likely result,” and similar expressions and
include statements regarding long-term weight loss maintenance on
the Allurion Program, Allurion’s expectations for, and market
acceptance of, Allurion’s Virtual Care Suite and the Allurion
Program in general, Allurion’s ability to scale its business,
including the VCS, and the ability of the Allurion Program
components to improve clinical and patient outcomes.
Forward-looking statements are predictions, projections and other
statements about future events that reflect the current beliefs and
assumptions of Allurion’s management based on information currently
available to them and, as a result, are subject to risks and
uncertainties. Many factors could cause actual future results or
developments to differ materially from the forward-looking
statements in this communication, including but not limited to (i)
the ability of Allurion to obtain and maintain regulatory approvals
for and successfully commercialize the Allurion Program, including
the Allurion Balloon and the VCS, (ii) the timing of, and results
from, our clinical studies and trials, (iii) the evolution of the
markets in which Allurion competes, (iv) the ability of Allurion to
defend its intellectual property, (v) the impact of the COVID-19
pandemic, the Russia and Ukraine war, and the Israel-Hamas conflict
on Allurion’s business, (vi) Allurion’s expectations regarding its
market opportunities, including those for the VCS platform, and
(vii) the risk of economic downturns and a changing regulatory
landscape in the highly competitive industry in which Allurion
operates. The foregoing list of factors is not exhaustive. You
should carefully consider the foregoing factors and the other risks
and uncertainties described in the “Risk Factors” section of
Allurion’s Annual Report on Form 10-K filed on March 26, 2024 and
other documents filed by Allurion from time to time with the U.S.
Securities and Exchange Commission. These filings identify and
address other important risks and uncertainties that could cause
actual events and results to differ materially from those contained
in the forward-looking statements. Forward-looking statements speak
only as of the date they are made. Readers are cautioned not to put
undue reliance on forward-looking statements, and Allurion assumes
no obligation and does not intend to update or revise these
forward-looking statements, whether as a result of new information,
future events, or otherwise. Allurion does not give any assurance
that it will achieve its expectations.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240502755499/en/
Global Media: Cedric Damour PR Manager +33 7 84 21 02 20
cdamour@allurion.com Investors Mike Cavanaugh, Investor
Relations ICR Westwicke (617) 877-9641
mike.cavanaugh@westwicke.com
Allurion Technologies (NYSE:ALUR)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Allurion Technologies (NYSE:ALUR)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024
